Oxford Biomedica (OXB) Share Price, News & Analysis

Company Overview

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

Key Stats

• Today's Range: 295 to 309.50
• 50-Day Range: 232.50 to 382
• 52-Week Range: 220.52 to 455
• Volume: 72,561 shs
• Average Volume: 288,832 shs
• Market Capitalization: £318.37 million
• P/E Ratio: N/A
• Dividend Yield: 4.57%
• Price Target: GBX 560
• Consensus Rating: Moderate Buy

OXB Stock Analysis - Frequently Asked Questions

How have OXB shares performed this year?

Oxford Biomedica's stock was trading at GBX 420 on January 1st, 2025. Since then, OXB shares have decreased by 28.7% and is now trading at GBX 299.50.
View the best growth stocks for 2025 here.

How were Oxford Biomedica's earnings last quarter?

Oxford Biomedica plc (LON:OXB) posted its earnings results on Wednesday, April, 9th. The biopharmaceutical company reported ($41.75) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative trailing twelve-month return on equity of 202.50%.
Read the conference call transcript.

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Barclays (BARC).

Company Calendar

• Last Earnings: 4/09/2025
• Today: 4/26/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OXB
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: +44-1865-783000
• Fax: N/A
• Employees: 891
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 560
• High Stock Price Target: GBX 740
• Low Stock Price Target: GBX 380
• Potential Upside/Downside: +87.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (134.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-143,513,452.58
• Net Margins: -145.98%
• Pretax Margin: N/A
• Return on Equity: -202.50%
• Return on Assets: -12.67%

Debt

• Debt-to-Equity Ratio: 166.48
• Current Ratio: 2.35
• Quick Ratio: 1.67

Sales & Book Value

• Annual Sales: £98.31 million
• Price / Sales: 3.24
• Cash Flow: GBX 99.62 per share
• Price / Cash Flow: 3.01
• Book Value: GBX 67.70 per share
• Price / Book: 4.42

Miscellaneous

• Outstanding Shares: 106,301,077
• Free Float: N/A
• Market Cap: £318.37 million
• Optionable: Not Optionable
• Beta: 1.09